Paul Bulcke - Roche Holding Non-Executive Director
| ROGN Stock | MXN 4,172 87.64 2.06% |
Director
Mr. Paul Bulcke has served as NonExecutive Independent Director at Roche Holding Ltd since March 1, 2011. He is Member of the Audit Committee at the Company. He started his career in 1977 as Financial Analyst with Scott Graphics International. In 1979 he joined Nestle Group where he held several position including Marketing trainee, sales and division functions, Market Head at Nestle Portugal, Nestle Chech and Slovak Republic, as well as at Nestle Germany. Between 2004 and 2008, Mr. Bulcke acted as Executive Vice President, Nestle S.A. as well as Zone Director for Zone Americas United States of America, Canada, Latin America and Caribbean. Mr. Bulcke was Chief Executive Officer of Nestle S.A. since April 2008. He studied Commercial Engineering at Katholieke Universiteit Leuven, from which he graduated in 1976. Between 1976 and 1977 he attended postgraduate studies in Management at Vlerick Leuven Gent Management School, and in 1995 he completed Program for Executive Development at Institute of Management Development Switzerland. since 2011.
| Age | 64 |
| Tenure | 13 years |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Thomas Lynch | Bristol Myers Squibb | 57 | |
| Christian Mulliez | Sanofi | 57 | |
| Stephen Sherwin | Biogen Inc | 69 | |
| Greg Garland | Amgen Inc | 56 | |
| Alan Lacy | Bristol Myers Squibb | 64 | |
| Brian Posner | Biogen Inc | 56 | |
| Laurent Attal | Sanofi | 60 | |
| Franklyn Prendergast | Eli Lilly and | 70 | |
| Gerard Kemmel | Sanofi | 74 | |
| Bernard Charles | Sanofi | 61 | |
| Jose Baselga | Bristol Myers Squibb | 57 | |
| Bonnie Bassler | Sanofi | N/A | |
| Nancy Leaming | Biogen Inc | 70 | |
| Michael Grobstein | Bristol Myers Squibb | 75 | |
| Raul Alvarez | Eli Lilly and | 61 | |
| Ellen Kullman | Amgen Inc | 62 | |
| Matthew Emmens | Bristol Myers Squibb | 66 | |
| Ralph Alvarez | Eli Lilly and | 62 | |
| Diane Souza | Sanofi | 65 | |
| Christophe Babule | Sanofi | N/A | |
| Judith Pelham | Amgen Inc | 69 | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding AG Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Schadler, Head Communications | ||
| Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | ||
| Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | ||
| Bruno Eschli, Head Relations | ||
| Silvia Ayyoubi, Member of the Corporate Executive Committee, Head of Group Human Resources | ||
| Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Beatrice Mauro, Non-Executive Director | ||
| Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
| William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
| Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | ||
| James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | ||
| Gottlieb Keller, Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors | ||
| Urs Jaisli, Chief Compliance Officer | ||
| Daniel ODay, Member of the Corporate Executive Committee, COO Division Roche Pharmaceuticals | ||
| Claudia Bockstiegel, G Counsel | ||
| DeAnne Julius, Non-Executive Director | ||
| Johannes MD, Head Devel | ||
| Karl Mahler, Head of Investor Relations | ||
| Andre Hoffmann, Non-Executive Vice Chairman of the Board | ||
| John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | ||
| Claudia Dyckerhoff, Non-Executive Director | ||
| Fritz Gerber, Honorary Chairman of the Board | ||
| Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications | ||
| Julie Brown, Non-Executive Director | ||
| Richard Lifton, Non-Executive Director | ||
| Paul Bulcke, Non-Executive Director | ||
| Christoph Franz, Non-Executive Director | ||
| PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office | ||
| Pascale Schmidt, Chief Officer | ||
| Pius Baschera, Non-Executive Director | ||
| Peter Voser, Non-Executive Director | ||
| Bernard Poussot, Non-Executive Director | ||
| John Bell, Non-Executive Director | ||
| Andreas Oeri, Non-Executive Director | ||
| Alan Hippe, Member of the Corporate Executive Committee, CFO, Information Technology Officer | ||
| William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | ||
| F Hoffmann, IR Contact Officer | ||
| Severin Schwan, Chairman of the Corporate Executive Committee, CEO, Director | ||
| Anita Hauser, Non-Executive Director | ||
| Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 5.83 T | |||
| Shares Outstanding | 693.89 M | |||
| Shares Owned By Institutions | 40.30 % | |||
| Price To Earning | 421.29 X | |||
| Price To Book | 9.80 X | |||
| Price To Sales | 79.71 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Roche Holding in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Roche Holding's short interest history, or implied volatility extrapolated from Roche Holding options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Roche Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |